A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Oct 22, 2026

European Commission Expands PADCEV™ (enfortumab vedotin) Plus Keytruda® (pembrolizumab) Approval to Adults with Resectable Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

- Expanded indication provides an approved perioperative treatment option for adult patients with resectable MIBC in the European Union - - Approval is based on Phase 3 EV-304 results...

Read more about European Commission Expands PADCEV™ (enfortumab vedotin) Plus Keytruda® (pembrolizumab) Approval to Adults with Resectable Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Oct 8, 2026

Astellas Ranked First in the Pharmaceutical Sector in the Securities Analysts Association of Japan’s “2026 Award for Excellence in Corporate Disclosure”

TOKYO, October 8, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the company has ranked first in the pharmaceuticals sector for...

Read more about Astellas Ranked First in the Pharmaceutical Sector in the Securities Analysts Association of Japan’s “2026 Award for Excellence in Corporate Disclosure”
Oct 6, 2026

Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026

– PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable survival benefit in advanced bladder cancer – – VYLOY™ (zolbetuximab) research reinforces the role of CLDN18.2 in...

Read more about Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026
Sep 23, 2026

Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D- Mutated Advanced Non-Small Cell Lung Cancer

- Study evaluates novel, investigational KRAS G12D-targeted protein degrader setidegrasib versus docetaxel in previously treated patients with advanced NSCLC - - Milestone marks second Phase 3...

Read more about Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D- Mutated Advanced Non-Small Cell Lung Cancer
Sep 17, 2026

PADCEV™ (enfortumab vedotin) in Combination with Keytruda® (pembrolizumab) Receives Positive CHMP Opinion for the Treatment of Adults with Resectable Muscle-Invasive Bladder Cancer

- Opinion based on data from pivotal Phase 3 EV-304 trial, which showed a 47% reduction in the risk of tumor recurrence, progression or death and a 35% reduction in the risk of death for the...

Read more about PADCEV™ (enfortumab vedotin) in Combination with Keytruda® (pembrolizumab) Receives Positive CHMP Opinion for the Treatment of Adults with Resectable Muscle-Invasive Bladder Cancer

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts